

Supplementary Table.S5 Adjuvant treatment for patients after surgery*.

Items		Chemotherapy	Radiation	Targeted	Endocrine
		No. (%)	No. (%)	therapy	therapy
				No. (%)	No. (%)
Molecular subtypes	Luminal (HER2-)	317(45.0%)	455(64.5%)	15(2.1%)	511(72.5%)
	HER2+	194(35.0%)	330(59.6%)	381(68.8%)	209(37.7%)
	TNBC	162(59.3%)	182(66.7%)	4(1.5%)	12(4.4%)
	P value	<0.001	0.078	<0.001	<0.001
Clinical stages	cT1-2N0	183(47.4%)	153(39.6%)	82(21.2%)	160(41.5%)
	cT1-2N1	296(44.0%)	444(66.0%)	175(26.0%)	339(50.4%)
	LABC	194(41.0%)	370(78.2%)	143(30.2%)	233(49.3%)
	P value	0.171	<0.001	0.012	0.015
NAT cycles	4-6	527(57.8%)	535(58.7%)	188(20.6%)	421(46.2%)
	>6	146(23.5%)	432(69.6%)	212(34.1%)	311(50.1%)
	P value	<0.001	<0.001	<0.001	0.137

*Adjuvant treatment data was available for 1532 patients.

Abbreviations: HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; NAT, neoadjuvant therapy.